Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Norheim I, Öberg K, Theodorsson-Norheim E et al. (1987) Malignant carcinoid tumours; An Analysis of 103 patients with regard to tumour localization hormone production and survival. Ann Surg 206:115–125
Berge T, Lindell F (1976) Carcinoid tumours. Scand Sect A 84:322–330
Surveillance Epidemiology and End Results (SEER) Program: Division of Cancer Prevention and Control, National Cancer Institute, Bethesda MD (unpublished data)
Williams ED, Sandler M (1963) The classification of carcinoid tumour. Lancet i:238–239
Moertel CG (1987) An odyssey in the land of small tumors. J Clin Oncol 5:1503–1522
Johnson LA, Lavin P, Moertel CG et al. (1983) Carcinoids: The association of histologic growth pattern and survival. Cancer 51:882–889
Godwin JD (1975) An analysis of 2837 cases. Cancer 36:560–569
Moertel CG, Sauer WG, Dockerty MB, Baggentoss AH (1961) Life history of the carcinoid tumor of the small intestine. Cancer 901–912
Carrasco CH, Charusangavej C, Ajani J et al. (1986) The carcinoid syndrome; palliation by hepatic artery embolization. Am J Radiology 147:149–154
Moertel CG, Hanley JA (ECOG) (1979) Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2:327–334
Öberg K, Norheim I, Lundqvist G, Wide L (1987) Cytotoxic treatment in patients with malignant carcinoid tumors; Response to streptozocin — alone or in combination with 5-FU; Acta Oncol 26:429–432
Ridolfi R, Amaducci L, Demi S et al. (1991) Chemotherapy with 5-Fluorouracil and Streptozotocin in carcinoid tumors of gastrointestinal origin: Experiences with 13 patients. J of Chemotherapy 3:328–331
Moertel CG, Rubin J, O’Connel MJ (1986) Phase II study of Cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Treat Rep 70:1459–1460
Rougier Ph, Okiveira J, Ducreux M et al. (1991) Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-Flourouracil, Doxorubicin and Cisplatin. Eur J Cancer 27:1380–1382
Moertel CG, Kvols LK, O’Connel MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 68:227–232
Moertel CG, Rubin J, Kvols K (1989) Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 7 (7): 865–868
Schober C, Schuppert F, Schmoll E et al. (1989) Interferon alpha-2b in patients with advanced carcinoids and apudoma. Blut, (abstract 34th Ann Cong German Soc Hematol + Oncol) Hannover, Oct 1–4 59 (3): 331
Hanssen LE, Schrumpf E, Kolbenstvedt AN et al. (1989) Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha-2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol 24:787–795
Bartsch HH, Stockmann F, Arnold R, Creutzfeld W (1990) Treatment of patients with metastatic carcinoid tumors by recombinant human interferon-alpha -results from a phase II study. J Cancer Res Clin Oncol (15th Intl Cancer Cong Hamburg, Aug 16–22 1990). 116:305
Valimäki M, Jarvinen H, Salmela P et al. (1991) Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested ? Cancer 67:547–549
Öberg K, Norhim I, Lind E et al. (1986) Treatment of malignant carcinoid tumors with human leukocyte interferon. Long-term results. Cancer Treat Rep 70:1297–1304
Öberg K, Alm G, Magnusson A et al. (1989) Treatment of malignant tumors with recombinant interferon alpha-2b (Intron-A); Development of neutralizing interferon antibodies and possible loss of antitumor activity. J Nat Can Inst 81:531–535
Öberg K, Eriksson B (1991) The role of interferons in the management of carcinoid tumours: Acta Oncol 30:519–522
Tiensuu Janson E, Rönnblom L, Ahlström H et al. (1992) Treatment with alpha-interferon versus alpha-interferon in combination with streptozotocin and doxorubicin in patients with malignant carcinoid tumors: A randomized trial. Annals of Oncol 3:635–638
Biesma B, Willemse PHB, Mulder NH et al. (1992) Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers. Br J Cancer 66:850–855
Tiensuu Janson E, Ahlström H, Andersson T, Öberg KE (1992) Octreotide and Interferon alfa: A new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 28A: 1647–1650
Kvols LK, Moertel CG, O’Connell MJ et al. (1986) Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663–666
Öberg K, Norheim I, Theodorsson E (1991) Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol 30:503–507
Vinik AI, Thompson N, Eckhauser F, Moattari AR (1989) Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. Acta Oncol 28:389–402
Buchanan KD, Johnston LF, O’Hare MMT et al. (1986) Neuroendocrine tumors. A European view. Am J Med 81:14–22
Eriksson B, Arnberg H, Lindgren PG et al. (1990) Neuroendocrine pancreatic tumors: clinical presentation, biochemical and histopathological findings in 84 patients. J Int Med 228:103–113
Wilder RM, Allan FN, Power MH et al. (1927) Carcinoma of the islands of the pancreas. Hyperinsulinism and hypoglycemia. J Am Med Assoc 89:348–355
Zollinger RM, Ellison EH (1955) Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142:709–728
Verner-Morrison JV, Morrison AB (1958) Islet cell tumor and syndrome of refractory diarrhea and hypokalemia. Am J Med 25:374–380
Mallinson CN, Bloom SR, Warin AP et al. (1974) A glucagnoma syndrome. Lancet ii: 1–5
Ganda OP, Weir GC, Sveldner JS et al. (1977) „Somatostationoma”: A somatostatin containing tumor of the endocrine pancreas. N Engl J Med 296:963–967
Imura H (1980) Ectopic hormone syndromes. Clin Endocrinol Metab 9 (2):235–259
Kent RB, van Heerden J, Nejland L (1982) Non-functioning islet cell tumors. Ann Surg 193 (2): 185–190
Grimelius L, Wilander E (1980) Silver stains in the study of endocrine cells of the gut and pancreas. Invest Cell Pathol 3:3–12
Lloyd RV, Mermark T, Schmidt O et al. (1984) Immunohistochemical detection of chromogranin and neurone specific enolase in pancreatic endocrine neoplasms. Am J Surg Pathol 8:607–614
Eriksson B, Öberg K (1993) An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 32:203–208
Wellbourn RB, Wood M, Polak JM et al. (1981) In: Bloom SR, Polak JM (eds) Gut Hormones ed 2. Churchill Livingstone, London pp 547–554
Ajani Carrasco CH, Charnsangavej C et al. (1988) Islet cell tumors metastatic to the liver: Effective palliation by sequential hepatic artery embolization. Ann Intern Med 108:340–344
Moertel CG, Johnson M, McKusick M et al. (1994) The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Int Med 120:302–309
Tennvall J, Ljungberg B, Gustavsson A et al. (1992) Radiotherapy for unresectable endocrine pancreatic carcinomas. Eur J of Surg Oncology 18:73–76
Moertel CG, Lefkopoulo M, Lipsitz M (1992) Streptozocin — doxorubicin, or Chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (8):519–523
Malvligit G, Pollock R, Evans H, Wallace S (1993) Durable hepatic tumor regression after arterial chemoembolization-infusion in patients with islet cell carcinoma of the pancreas metastatic to the liver. Cancer 72:375–380
Eriksson B, Öberg K, Alm G et al. (1986) Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Lancet ii: 1307–1309
Kvols L, Buck M, Moertel CG et al. (1987) Treatment of Metastatic Islet Cell Carcinoma with a Somatostatin Analogue (SMS 201–995). Ann Intern Med 107:162–168
Broder LE, Carter SK (1973) Pancreatic islet cell carcinoma. Results of therapy with streptozocin in 52 patients. Ann Intern Med 79:108–118
Moertel CG, Lavin P, Hahn G (1982) Phase II Trial of Doxorubicin Therapy for Advanced Islet Cell Carcinoma. Cancer Treatm Rep 88 (7) : 1567–1569
Altimari A, Badrinath K, Reisel H et al. (1987) DTIC therapy in patients with malignant intraabdominal neuroendocrine tumors
von Schrenck T, Howard J, Doppman J (1988) Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterol 94:1326–1334
Eriksson B, Skogseid B, Lundqvist G (1990) Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65 (9): 1883–1890
Moertel CG, Kvol L, O’Connel et al. (1991) Treatment of neuroendocrine carcinomas with combined Etoposide and Cisplatin. Cancer 68:227–232
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Eriksson, B., Öberg, K. (1998). Neuroendokrine Darm- und Pankreastumoren (Apudome). In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10493-4_32
Download citation
DOI: https://doi.org/10.1007/978-3-662-10493-4_32
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-63821-6
Online ISBN: 978-3-662-10493-4
eBook Packages: Springer Book Archive